KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Debt to Equity (2016 - 2025)

Boston Scientific's Debt to Equity history spans 17 years, with the latest figure at $0.47 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 5.33% year-over-year to $0.47; the TTM value through Dec 2025 reached $0.47, down 5.33%, while the annual FY2025 figure was $0.47, 5.33% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.47 at Boston Scientific, down from $0.49 in the prior quarter.
  • Across five years, Debt to Equity topped out at $50.59 in Q1 2023 and bottomed at -$4.04 in Q4 2021.
  • The 5-year median for Debt to Equity is $0.47 (2023), against an average of $3.86.
  • The largest annual shift saw Debt to Equity plummeted 971.79% in 2021 before it surged 257908.43% in 2023.
  • A 5-year view of Debt to Equity shows it stood at -$4.04 in 2021, then soared by 110.97% to $0.44 in 2022, then increased by 5.19% to $0.47 in 2023, then grew by 5.91% to $0.49 in 2024, then dropped by 5.33% to $0.47 in 2025.
  • Per Business Quant, the three most recent readings for BSX's Debt to Equity are $0.47 (Q4 2025), $0.49 (Q4 2024), and $6.45 (Q2 2024).